key: cord-0823813-sr668fyw
authors: Akashi, Y.; Kiyasu, Y.; Takeuchi, Y.; Kato, D.; Kuwahara, M.; Muramatsu, S.; Ueda, A.; Notake, S.; Nakamura, K.; Ishikawa, H.; Suzuki, H.
title: Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2
date: 2021-06-13
journal: nan
DOI: 10.1101/2021.06.09.21258157
sha: 08b8cea844a963241abe15e22dfa5e586bec7c6c
doc_id: 823813
cord_uid: sr668fyw

Antigen tests for severe acute respiratory coronavirus 2 sometimes show positive lines earlier than their specified read time, although the implication of getting the results at earlier time is not well understood. This study aimed to evaluate the clinical utility of an antigen test by evaluating the time period to get positive results and by comparing the test sensitivity with that of a digital immunoassay (DIA) test. We prospectively collected additional nasopharyngeal samples from patients who had already tested positive for SARS-CoV-2 by reverse transcription PCR. The additional swab was used for an antigen test, QuickNavi-COVID19 Ag, and the time periods to get positive results were measured. The sensitivity of QuickNavi-COVID19 Ag was also compared with that of a DIA. In 84 of 96 (87.5%) analyzed cases, the results of QuickNavi-COVID19 Ag were positive. The time to obtain positive results was 15.0 seconds in median (inter quartile range: 12.0-33.3, range 11-736), and was extended in samples with higher cycle thresholds (Ct) (p<0.001). Positive lines appeared within a minute in 85.7% of cases and within 5 minutes in 96.4%. The sensitivities of QuickNavi-COVID19 Ag and the DIA were 87.5% (95% confident interval [CI]: 79.2%-93.4%) and 88.6% (95%CI: 75.4%-96.2%), respectively. Their results were concordant in 90.9% of cases, with discrepancies present only in cases with Ct values >32. QuickNavi-COVID19 Ag immediately showed positive results in most cases, and the time to a positive reaction may have indicated the viral load. In addition, the sensitivity of the test was comparable to the DIA.

Antigen tests for severe acute respiratory coronavirus 2 sometimes show positive lines earlier than their specified read time, although the implication of getting the results at earlier time is not well understood. This study aimed to evaluate the clinical utility of an antigen test by evaluating the time period to get positive results and by comparing the test sensitivity with that of a digital immunoassay (DIA) test.

We prospectively collected additional nasopharyngeal samples from patients who had already tested positive for SARS-CoV-2 by reverse transcription PCR. The additional swab was used for an antigen test, QuickNavi™-COVID19 Ag, and the time periods to get positive results were measured. The sensitivity of QuickNavi™-COVID19

Ag was also compared with that of a DIA. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 13, 2021.

The global pandemic caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) remains a concern and is unlikely to end soon [1] . Until the pandemic is under control, early diagnosis and screening with effective test modalities are essential strategies to combat the disease [2] .

Antigen tests originally had low sensitivity compared to nucleic examinations [3] . Their diagnostic performance has improved over time [4] , and previous research has found them beneficial for screening purposes [5] or in low-resource settings [6] .

Advantages of antigen tests include the ability to analyze multiple samples simultaneously, the lack of a need for special equipment, and the fast turnaround time (TAT).

Manufacturers of antigen tests recommend that the results be read 10-30 minutes after sample placement [3] . Positive lines sometimes appear before the manufacturer's specified time, although the clinical implication of an early detection is not well understood. Knowing the time to a positive reaction in clinical samples may help identify a more appropriate read time, which could reduce their overall TAT.

We previously evaluated the diagnostic performance of QuickNavi™-COVID19 Ag (Denka Co., Ltd., Tokyo, Japan), revealing a sensitivity of 86.7% and a specificity of 100% [7], with a read time of 15 minutes. The sensitivity seemed sufficient, although the limit of detection was inferior to that of a rapid immunochromatography, which utilizes a digital immunoassay (DIA) platform [8] . The head-to-head comparison using clinical samples has been awaited to validate their test performances.

In this study, we aimed to clarify the clinical utility of QuickNavi™-COVID19 Ag by evaluating the time periods to get positive results and by comparing its sensitivity . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 13, 2021. ; https://doi.org/10.1101/2021.06.09.21258157 doi: medRxiv preprint with an immunochromatography test, which comes with a DIA reader.

Between January 25, 2021, and March 27, 2021, we prospectively evaluated the time necessary for positive reactions in two antigen tests; one is QuickNavi™-COVID19 Ag, which is already on the market with 15 minutes read time, and the other is its improved product (DK20-CoV-8M). Nasopharyngeal samples were obtained from SARS-CoV-2-positive patients after they provided informed consent. The ethics committee of Tsukuba Medical Center Hospital (TMCH) approved the present study (approval number: 2020-033).

This study was performed at a drive-through-type PCR center located at TMCH in Tsukuba, Japan. The PCR center performed in-house RT-PCR examinations [7] of residents of the Tsukuba district who were referred from a local public health center and primary care facilities ( Figure 1 ). PCR examination was performed immediately after each nasopharyngeal sampling, and the results were reported to both patients and doctors within a few hours. Physicians then assessed the risk factors and disease severity of PCRpositive patients ( Figure 1 ).

In the current study, an additional nasopharyngeal sample was obtained from inhouse PCR-positive patients using FLOQSwab™ (Copan Italia S.p.A., Brescia, Italy), using a previously described technique [9] . The swab sample was diluted with specimen . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Research Laboratories, Inc., Japan) was used as a control to make a standard curve for the analysis of copy numbers.

During the study period, antigen testing was performed with both QuickNavi™-COVID19 Ag and QuickChaser Auto SARS-CoV-2 (Mizuho Medy Co., Ltd.) at the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 13, 2021. ; https://doi.org/10.1101/2021.06.09.21258157 doi: medRxiv preprint drive-through-type PCR center. We compared the analytical sensitivity for the detection of SARS-CoV-2 between the two antigen tests. The results of real-time RT-PCR of SARS-CoV-2 were used as the reference standard.

The sensitivity of antigen testing was calculated using the Clopper and Pearson method, with 95% confident intervals (95% CI). Linear regression analysis was used to describe the relationship between two continuous variables; p-values <0.05 were considered to represent statistically significant differences. All calculations were conducted using R 4.0.4 (The R Foundation, Vienna, Austria).

The study included 96 patients who were positive for SARS can be tested within 1 minute and over 90% within 5 minutes, which is faster than designated read time. The manufacturer's specified time, therefore, may be longer than necessary ( Figure 3 ). This finding might apply to other antigen tests, although variations in performance possibly exist due to methodological differences among products [12] .

The time period to obtain positive results extended proportionally with the Ct value; hence, the time required to be positive may indicate the viral load in a given sample.

In our study, the time needed more than 10 minutes was limited to the cases with a Ct value >30. Given that these samples are generally culture negative [13] , positive lines that appears more than a few minutes may imply a low viral load with a smaller risk of transmissivity to others. Viral load is associated with disease severity [14] in addition to transmissivity. A shorter reaction time in antigen tests might predict disease severity, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 13, 2021. ; https://doi.org/10.1101/2021.06.09.21258157 doi: medRxiv preprint considering that reaction time was employed in a clinical score to predict the severity of pneumococcal pneumonia [15] . Further studies should be conducted to evaluate the clinical usefulness of measuring the time to get positive results in various antigen tests.

We expected DIA to have a higher sensitivity than QuickNavi™-COVID19 Ag because of its lower limit of detection and its implementation of a digital immunoassay This study had several limitations. First, it did not include patients who were confirmed to be negative for SARS-CoV-2 by RT-PCR. The relationship between QuickNavi™-COVID19 Ag read times and the possibility of false positives was not evaluated, although we previously confirmed false positives are merely seen with this test [7] . Further, we could not compare the specificities of QuickNavi™-COVID19 Ag and the DIA evaluated. Second, we did not assess whether differences in strains or sample characteristics (e.g., viscosity, blood inclusion) influenced the time to get positive results.

In conclusion, QuickNavi™-COVID19 Ag yielded a positive result immediately after sample placement in most cases, and the time needed for final interpretation was longer in samples with larger Ct values. The sensitivity was comparable to that of the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 13, 2021. ; https://doi.org/10.1101/2021.06.09.21258157 doi: medRxiv preprint 11 DIA.

We thank all staff at the Department of Clinical Laboratory of Tsukuba Medical Center Hospital who contributed to this study, and all medical institutions that provided their patients' clinical information.

Denka Co., Ltd., and Mizuho Medy Co., Ltd. provided test kits free of charge.

Regarding this study, Hiromichi Suzuki received lecture fees from Denka Co., Ltd., and Otsuka Pharmaceutical Co., Ltd., and a consultation fee from Mizuho Medy Co., Ltd.

Daisuke Kato, Miwa Kuwahara, and Shino Muramatsu are employed by Denka Co., Ltd., the developer of QuickNavi™-COVID19 Ag.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 13, 2021. The time to a positive reaction was not available for DIA due to the nature of digital immunoassays. The running time of its reader is 15 minutes.

The RT-PCR of the N2 gene was used as a reference.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 13, 2021. ; https://doi.org/10.1101/2021.06.09.21258157 doi: medRxiv preprint

World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update

Centers for Disease Control and Prevention. Testing Strategies for SARS-CoV

World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays

Preventing COVID-19 spread in closed facilities by regular testing of employees-An efficient intervention in long-term care facilities and prisons?

Rapid antigen screening of asymptomatic people as a public health tool to combat COVID-19

International license for SARS-CoV-2, (2021) Accessed

Vitro Diagnostics EUAs -Antigen Diagnostic Tests for SARS

Viral cultures for COVID-19 infectious potential assessment -a systematic review

SARS-CoV-2 viral load is associated with increased disease severity and mortality

A new urinary antigen test score correlates with severity of pneumococcal pneumonia in children

Prospective analytical performance evaluation of the QuickNavi TM -COVID19 Ag for asymptomatic individuals

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) MedRxiv

Comparison of Rapid Antigen Tests for COVID-19

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 13, 2021. [11] Centers for Disease Control and Prevention. Interim Guidance for Antigen Testing . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted June 13, 2021. ; https://doi.org/10.1101/2021.06.09.21258157 doi: medRxiv preprint